223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide-MedSci.cn

223Ra in asymptomatic patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) who progressed to first-line abiraterone acetate or enzalutamide

Carles, J; Alonso, T; Gonzalez, BM; Vidal, MJM; Estevez, SV; del Alba, AG; Piulats, JM; Garcia, PB; Gallardo, E; Barrera, RM; Paredes, P; Reig, O; de Espana, CG; Collado, R; Bonfill, T; Suarez, C; Malfettone, A; Garde, J

ANNALS OF ONCOLOGY, 2020; 31 (): S525

科室
- - 订阅+
  - 更多科室
工具
服务